Abstract LB-433: Biomarker analysis and final results of INT70/09 Phase II proof-of-concept study of Pazopanib (PZP) in refractory urothelial cancer (UC)

Mapping Intimacies ◽

10.1158/1538-7445.am2012-lb-433 ◽

2012 ◽

Cited By ~ 2

Author(s):

Andrea Necchi ◽

Nadia Zaffaroni ◽

Luigi Mariani ◽

Nicola Nicolai ◽

Flavio Crippa ◽

...

Keyword(s):

Phase Ii ◽

Urothelial Cancer ◽

Proof Of Concept ◽

Concept Study ◽

Biomarker Analysis

Download Full-text

Abstract PS10-27: A phase II proof-of-concept study of palbociclib (P) rechallenge in patients (pts) with hormone receptor (HR)[+]/HER2[-] metastatic breast cancer (MBC) and clinical benefit to prior P-based treatment (BIOPER)

10.1158/1538-7445.sabcs20-ps10-27 ◽

2021 ◽

Author(s):

Antonio Llombart-Cussac ◽

Javier Cortés ◽

Beatriz Bellosillo Paricio ◽

Miguel Gil Gil ◽

Giuseppe Curigliano ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Phase Ii ◽

Clinical Benefit ◽

Hormone Receptor ◽

Metastatic Breast ◽

Proof Of Concept ◽

Concept Study

Download Full-text

The antiproliferative effect of pasireotide LAR alone and in combination with everolimus (RAD001) in patients with progressive medullary thyroid cancer (MTC): A single-center, open-label, phase II, proof-of-concept study.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.tps219 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. TPS219-TPS219

Author(s):

A. Faggiano ◽

A. Colao

Keyword(s):

Thyroid Cancer ◽

Phase Ii ◽

Medullary Thyroid Cancer ◽

Antiproliferative Effect ◽

Proof Of Concept ◽

Single Center ◽

Open Label ◽

Medullary Thyroid ◽

Concept Study ◽

Open Label Phase

Download Full-text

A Triple Combination Tailored Therapy (Folfiri-Cetuximab) for Safe Dose Intensification: A Multicenter Phase II Proof-Of-Concept Study.

Annals of Oncology ◽

10.1093/annonc/mdu164.7 ◽

2014 ◽

Vol 25 ◽

pp. ii7

Author(s):

O. Capitain ◽

J.P. Metges ◽

M. Boisdron-Celle ◽

A. Adenis ◽

J.L. Raoul ◽

...

Keyword(s):

Phase Ii ◽

Proof Of Concept ◽

Triple Combination ◽

Tailored Therapy ◽

Dose Intensification ◽

Concept Study ◽

Multicenter Phase ◽

Safe Dose

Download Full-text

Phase II proof-of-concept study of atiprimod in patients with advanced low- to intermediate-grade neuroendocrine carcinoma

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.4611 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 4611-4611 ◽

Cited By ~ 8

Author(s):

M. W. Sung ◽

L. Kvols ◽

G. Jacob ◽

C. Talluto ◽

J. C. Torres ◽

...

Keyword(s):

Phase Ii ◽

Neuroendocrine Carcinoma ◽

Proof Of Concept ◽

Intermediate Grade ◽

Concept Study

Download Full-text

Phase Ii, Multicenter, Open-Label, Proof of Concept Study of Tasquinimod in Patients with Advanced Hepatocellular (Hcc), Ovarian (Oc), Renal Cell (Rcc) and Gastric (Gc) Carcinomas

Annals of Oncology ◽

10.1093/annonc/mdu331.40 ◽

2014 ◽

Vol 25 ◽

pp. iv160

Author(s):

A.M. Oza ◽

R. Plummer ◽

I.B. Vergote ◽

F. Thistlethwaite ◽

G.A. Bjarnason ◽

...

Keyword(s):

Phase Ii ◽

Renal Cell ◽

Proof Of Concept ◽

Open Label ◽

Concept Study

Download Full-text

A single-center, open-label, phase II, proof-of-concept study with pasireotide long-acting release in patients with progressive medullary thyroid cancer: 6-month evaluation

Endocrine Abstracts ◽

10.1530/endoabs.32.p1080 ◽

2013 ◽

Author(s):

Antongiulio Faggiano ◽

Piero Ferolla ◽

Giovanni Vitale ◽

Prete Michela Del ◽

Valeria Ramundo ◽

...

Keyword(s):

Thyroid Cancer ◽

Phase Ii ◽

Medullary Thyroid Cancer ◽

Proof Of Concept ◽

Single Center ◽

Open Label ◽

Medullary Thyroid ◽

Concept Study ◽

Open Label Phase ◽

Long Acting

Download Full-text

Efficacy of Mirogabalin (DS-5565) on Patient-Reported Pain and Sleep Interference in Patients with Diabetic Neuropathic Pain: Secondary Outcomes of a Phase II Proof-of-Concept Study

Pain Medicine ◽

10.1093/pm/pnw342 ◽

2017 ◽

Cited By ~ 2

Author(s):

Domenico Merante ◽

Julio Rosenstock ◽

Uma Sharma ◽

Karen Feins ◽

Ching Hsu ◽

...

Keyword(s):

Neuropathic Pain ◽

Phase Ii ◽

Proof Of Concept ◽

Diabetic Neuropathic Pain ◽

Concept Study ◽

Patient Reported ◽

Secondary Outcomes ◽

Sleep Interference

Download Full-text

A phase II, multi-centre, randomised, double-blind, placebo-controlled, parallel group, proof of concept study to compare the efficacy, safety and tolerability of PSD502, delivered topically onto the upper vagina and cervix, to placebo in controlling discomfort/pain intensity in subjects undergoing outpatient hysteroscopy

http://isrctn.org/> ◽

10.1186/isrctn46090514 ◽

2012 ◽

Author(s):

Wlodzimierz Baranowski

Keyword(s):

Pain Intensity ◽

Phase Ii ◽

Proof Of Concept ◽

Double Blind ◽

Double Blind Placebo ◽

Concept Study ◽

Parallel Group ◽

Outpatient Hysteroscopy

Download Full-text

PP 31 INT70/09 Phase II study of Pazopanib (PZP) monotherapy for patients (pts) with relapsed/refractory urothelial cancer (UC): updated results of a proof-of-concept trial

European Journal of Cancer ◽

10.1016/s0959-8049(11)72683-1 ◽

2011 ◽

Vol 47 ◽

pp. S25

Author(s):

A. Necchi ◽

N. Nicolai ◽

C. Ortega ◽

T. Sava ◽

C. Sacco ◽

...

Keyword(s):

Phase Ii ◽

Urothelial Cancer ◽

Phase Ii Study ◽

Proof Of Concept

Download Full-text

Leveraging a Clinical Phase Ib Proof-of-Concept Study for the GPR40 Agonist MK-8666 in Patients With Type 2 Diabetes for Model-Informed Phase II Dose Selection

Clinical and Translational Science ◽

10.1111/cts.12479 ◽

2017 ◽

Vol 10 (5) ◽

pp. 404-411 ◽

Cited By ~ 3

Author(s):

AW Krug ◽

P Vaddady ◽

RA Railkar ◽

BJ Musser ◽

J Cote ◽

...

Keyword(s):

Type 2 Diabetes ◽

Phase Ii ◽

Proof Of Concept ◽

Dose Selection ◽

Phase Ib ◽

Concept Study ◽

Clinical Phase

Download Full-text